Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease-Reference-Cited by-同舟云学术

Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease

Published:2023-03-25 Issue:4 Volume:201 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Towerman Alison S.¹²^ORCID,Guilliams Kristin P.³⁴⁵,Guerriero Réjean³,Shinawi Marwan S.⁶,Stoll Janis M.⁷,Willis Daniel N.¹,Hulbert Monica L.¹

Affiliation:

1. Division of Hematology/Oncology, Department of Pediatrics Washington University in St. Louis School of Medicine St. Louis Missouri USA

2. Trudy Busch Valentine School of Nursing Saint Louis University St. Louis Missouri USA

3. Division of Pediatric and Developmental Neurology, Department of Neurology Washington University in St. Louis School of Medicine St. Louis Missouri USA

4. Division of Critical Care Medicine, Department of Pediatrics Washington University in St. Louis School of Medicine St. Louis Missouri USA

5. Mallinckrodt Institute of Radiology Washington University in St. Louis School of Medicine St. Louis Missouri USA

6. Division of Genetics and Genomic Medicine, Department of Pediatrics Washington University in St. Louis School of Medicine St. Louis Missouri USA

7. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics Washington University in St. Louis School of Medicine St. Louis Missouri USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18770

Reference14 articles.

1. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults

2. Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report

3. Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot

4. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis

5. Pediatric Advisory Committee. Exjade®/Jadenu® (deferasirox) briefing document [Internet].United States: Food and Drug Administration;2018Sept 20 (cited 2023 March 22). p.1–14. Avalable from:https://www.fda.gov/media/164286/download

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quo vadis ureagenesis disorders? A journey from 90 years ago into the future;Journal of Inherited Metabolic Disease;2024-06-04

2. Multiple drugs;Reactions Weekly;2023-11-18